Emcure, the parent company of Gennova Biopharmaceuticals that's developing messenger RNA (mRNA) COVID-19 vaccine, said it is working on backward integration of its jab to reduce dependence on key imported raw materials, reagents and enzymes that go into the manufacturing.

"A lot of these key starting materials that go into the mRNA vaccine – Modernas and Pfizers of the world – rely on a lot of European and US suppliers. We saw that as a potential bottleneck," Vikas Thapar, President, Corporate Development & Strategy at Emcure, told Moneycontrol.

Leave a Reply

Your email address will not be published. Required fields are marked *

Gennova, which is developing a potential indigenous mRNA COVID-19 vaccine called HGCO19, has initiated the enrolment of volunteers for Phase I and II clinical trials for its mRNA vaccine candidate. The vaccine has successfully completed animal trials and the clinical trials are expected to be completed in the next two-three months.

Leave a Reply

Your email address will not be published. Required fields are marked *